A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
暂无分享,去创建一个
M. Shahin | M. Goodheart | L. Landrum | P. DiSilvestro | R. Schilder | M. Powell | S. Gaillard | M. Sill | J. Hoffman | Lainie P Martin